Skip to main content
main-content

21.08.2018 | Glaucoma | Ausgabe 11/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018

A cost minimisation analysis comparing iStent accompanying cataract surgery and selective laser trabeculoplasty versus topical glaucoma medications in a public healthcare setting in New Zealand

Zeitschrift:
Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 11/2018
Autoren:
Kelvin Ngan, Ewan Fraser, Sophie Buller, Alex Buller

Abstract

Purpose

To produce an economic comparison of the iStent ab interno trabecular microbypass implant accompanying cataract surgery and selective laser trabeculoplasty (SLT) as first-line treatment versus topical medications for open-angle glaucoma in New Zealand in 2016.

Methods

The current annual costs of 19 available fully subsidised topical glaucoma medications by Pharmaceutical Management Agency (Pharmac) in 2016 were identified. Adjustments for pharmacist prescribing charges and previously described wastage levels were applied. The costs to perform iStent implantation and the cost to perform SLT were obtained from the local distributors, with the latter taking into account staff and consumable cost. Procedure costs divided by eye drops’ cost produced a break-even level in equivalent years of eye drops use.

Results

The range of annual eye drop cost was NZD$42.25 to NZD$485.11, with an average of NZD$144.81. Comparison of annual eye drop cost with iStent cost revealed 3 of 19 (15.8%) drops breaking even within 5 years, 9 of 19 (47.3%) within 10 years, and 12 of 19 (63.2%) within 15 years. The cost of bilateral SLT performed by a consultant was NZD$102.30 (breaking even in 0.71 years). The equivalent cost for a registrar was NZD$97.59 (breaking even in 0.67 years).

Conclusion

Economically, the iStent would appear to be a reasonably cost-effective treatment for glaucoma patients undergoing cataract surgery in a public healthcare setting in New Zealand, particularly for those using more expensive topical glaucoma medications, whilst SLT appears to be a worthwhile consideration as a first-line treatment for glaucoma in New Zealand.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

07.09.2018 | Video plus | Ausgabe 11/2018

Einseitige kombinierte Augenmuskeloperation zur Korrektur der Esotropie

Videobeitrag zur Rücklagerung des M. rectus medialis und Faltung des M. rectus lateralis

24.08.2018 | Leitlinien, Stellungnahmen und Empfehlungen | Ausgabe 10/2018

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

Therapeutische Strategien, Stand 24.04.2018

20.08.2018 | Rehabilitation | CME | Ausgabe 10/2018 Open Access

Aktuelle Möglichkeiten der visuellen Rehabilitation

17.08.2018 | Das therapeutische und diagnostische Prinzip | Ausgabe 11/2018

Suprachoroidale Hydrogelplombe